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Neutrophils are best known for their critical role in host defense, for which they utilize
multiple innate immune mechanisms, including microbe-associated pattern recognition,
phagocytosis, production of reactive oxygen species, and the release of potent
proteases, mediators, antimicrobials, and neutrophil extracellular traps. Beyond their
well-established contribution to innate immunity, neutrophils were more recently reported
to interact with various other cell types, including cells from the adaptive immune
system, thereby enabling neutrophils to tune the overall immune response of the host.
Neutrophils express different receptors for IgG antibodies (Fcγ receptors), which facilitate
the engulfment of IgG-opsonized microbes and trigger cell activation upon cross-
linking of several receptors. Indeed, FcγRs (via IgG antibodies) confer neutrophils with
a key feature of the adaptive immunity: an antigen-specific cell response. This review
summarizes the expression and function of FcγRs on human neutrophils in health and
disease and how they are affected by polymorphisms in the FCGR loci. Additionally,
we will discuss the role of neutrophils in providing help to marginal zone B cells for the
production of antibodies, which in turn may trigger neutrophil effector functions when
engaging FcγRs.
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INTRODUCTION
Neutrophils are key players of the innate immune response. They are the most abundant leukocytes
in the human blood (4.5–11 × 103/mm3). Following a circadian rhythm, neutrophils are released
from the bone marrow (1–3) and circulate in the blood for 4–6 days (4, 5). If they are not attracted
to sites of inflammation, they will express markers of aged neutrophils, and preferentially home
to the liver, spleen, or bone marrow, where they undergo apoptosis and are cleared by resident
macrophages (6–8). This immunologically silent mechanism allows for maintaining a high number
of functional neutrophils in the blood (55–70% of all blood leukocytes in the periphery), while
guaranteeing a quick removal of deregulated or altered neutrophils. The tight control of neutrophil
homeostasis is critical for the organism as many of their effector functions [i.e., production
of reactive oxygen species (ROS), release of neutrophil extracellular traps (NETs), or granules
containing potent proteases and lipophosphatases (9)] bare the potential to be deleterious for the
host and damage surrounding tissues and organs.
Neutrophils express various receptors that enable them to respond almost instantaneously to
diverse inflammatory stimuli and danger signals. Among these, receptors for the constant region
of IgG immunoglobulins (FcγRs) stand out. They bestow on neutrophils the capacity to react
in an antigen-specific way—hence to acquire a key feature of the adaptive immunity. FcγRs
enable neutrophils to interact with and respond to monomeric or aggregated immunoglobulins,
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antigen–antibody immune complexes, and opsonized (antibody-
coated) particles, cells, or surfaces. Humans express six classical
FcγRs: FcγRI/CD64, FcγRIIA/CD32A, FcγRIIB/CD32B,
FcγRIIC/CD32C, FcγRIIIA/CD16A, and FcγRIIIB/CD16B
(Table 1). All these FcγRs bind at least two of the four different
human IgG subclasses with association constants (KA) ranging
from 8× 107 down to 2× 104 M−1 (10).
All FcγRs, except for FcγRIIB and FcγRIIIB, are classical
activating receptors. Their activating signals are transduced by
an immunoreceptor tyrosine-based activation motif (ITAM)
that is either present in the cytoplasmic domain of the
FcγR itself (FcγRIIA/FcγRIIC) or in an associated signaling
subunit, notably the FcRγ chain. Upon FcγR aggregation by
multimeric ligands, Src family kinases phosphorylate these
motifs, allowing the activation of a signaling cascade, involving
the spleen tyrosine kinase (SYK), phosphatidylinositol 3-kinase
(PI3K), phospholipase C (PLC)-γ, Rho, and Rac, resulting
in calcium mobilization, cell activation, cytokine/chemokine
production, and cell migration (11–13). Counterbalancing these
activating FcγRs, the inhibitory receptor FcγRIIB possesses
an immunoreceptor tyrosine-based inhibition motif (ITIM) in
its intracytoplasmic domain. Upon its co-engagement with
an activating receptor, the phosphorylated ITIM recruits the
inositol polyphosphate-5-phosphatase SHIP1 (14) that negatively
regulates the signaling cascades initiated by ITAM-containing
receptors (15–17). Moreover, several FCGR polymorphisms have
been described in humans, adding to the complexity of this
receptor family with overlapping functions and affinities for their
ligands that collaborate, regulate, or compete with each other to
tune cellular responses.
In this review, we will focus on IgG receptors (FcγRs) on
neutrophils and their role and regulation in steady state and
inflammatory conditions.
TABLE 1 | Classical FcγRs and their expression on neutrophils.
Structure
Name FcγRI FcγRIIA FcγRIIB FcγRIIC FcγRIIIA FcγRIIIB
CD CD64 CD32A CD32B CD32C CD16A CD16B
Gene FCGR1A FCGR2A FCGR2B FCGR2C FCGR3A FCGR3B
Alleles – H131 R131 I232 T232 Q57 stop57 V176 F176 NA1 NA2 SH
Affinity High Low to medium Low to medium Low to medium Low to medium Low to medium
Expression on resting
neutrophils
< 2,000 copies 30,000–60,000
copies
Low to none; increase when
2B4 promotor haplotype
Low to none Low to none 100,000–200,000
copies
Neutrophil expression in
inflammatory conditions
Up to 10-fold increased
expression in presence of
IFN-γ and G-CSF
Upregulated in
presence TNF-α
Low to none; increase when
2B4 promotor haplotype
Low to none Low to none 100,000–200,000
copies, subject to
shedding
EXPRESSION AND ROLE OF FCγR ON
NEUTROPHILS DURING HOMEOSTASIS
Blood neutrophils from healthy individuals express large
amounts of a rather atypical FcγR, the FcγRIIIB. FcγRIIIB
is a glycophosphatidylinositol (GPI)-anchored protein with
no signaling capacity on its own. It was first described on
neutrophils in 1982 with the means of a newly developed
monoclonal antibody (mAb, 3G8) that also recognizes FcγRIIIA
on monocytes and NK cells (18). Incubation of neutrophils
with 3G8 could efficiently block binding of rabbit IgG-opsonized
sheep erythrocytes and soluble rabbit IgG immune complexes
(ICs), demonstrating that the newly identified receptor is
an IgG Fc receptor (18). FcγRIIIB is one of the most
abundant proteins on the surface of neutrophils, with each
cell expressing between 100,000 and 200,000 copies (19). In
resting neutrophils, the receptor is equally distributed over the
cell membrane and is present in both low- and high-density
detergent-resistant membranes (DRMs) (20). Additionally,
intracellular storage compartments have been described that
allow rapid FcγRIIIB mobilization to the cell surface upon
receptor engagement (21, 22). Previously thought to have no
signaling function, it is now generally accepted that FcγRIIIB
can trigger neutrophil activation. Following multivalent cross-
linking, FcγRIIIB accumulates in high-density DRMs (20) and
elicits downstream signals, leading to Ca2+ mobilization, cell
adhesion, and degranulation, but not to respiratory burst (23–
27). The exact intracellular signaling cascade remains a matter
of debate (20, 27–29), but seems to involve phosphorylation of
the Src kinase Hck, mitogen-activated kinases (MAPKs) ERK
(extracellular signal regulated kinase), and p38 and the tyrosine
kinase Pyk2 (30–32). In this context, it is noteworthy that the
3G8 antibody, which is often used to block FcγRIIIB, can trigger
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intracellular Ca-mobilization and neutrophil aggregation on its
own. This cell activation requires co-engagement of another
neutrophil FcγR, FcγRIIA via the Fc portion of the intact
antibody (33). The main functions of neutrophil FcγRIIIB during
homeostasis are the removal of spontaneously forming ICs from
the vasculature, and the maintenance of the soluble FcγRIIIB
(sFcγRIIIB) pool. FcγRIIIB-bound ICs are internalized through
a mechanism used by GPI-anchored receptors and fluid-phase
endocytosis (27), thereby clearing ICs without triggering further
cell activation that could be deleterious to the host. sFcγRIIIB
is present in serum of healthy individuals at concentrations of
5 nM (34). It is generated by proteolytic cleavage of surface
FcγRIIIB on activated and apoptotic neutrophils (34, 35). Despite
its relative abundance, the function of sFcγRIIIB remains elusive.
sFcγRIIIB retains Fc-binding capacities and hence competes
with membrane low-affinity receptors to dampen Fc-dependent
immune reactions (36, 37). Due to the fact that FcγRIIIB binds
to multimeric IgG1 and IgG3, but not or poorly IgG2 or IgG4
(10), the biological activity of these latter IgG subclasses should
not be affected by sFcγRIIIB. Notably, both IgG2 and IgG4 also
bind less well to other low-affinity FcγRs (with the exception
of FcγRIIA-H131) (10). Adding to this possible immune-
modulatory function, it also has been reported that sFcγRIIIB
can bind to complement receptors CD11b/CD18 or CR3/Mac-
1 and CD11c/CD18 or CR4 via lectin/carbohydrate interactions
(38). These interactions can result in cytokine production by
neutrophils andmonocytes or may inhibit β2 integrin-dependent
adhesion and subsequent transendothelial migration (38).
Neutrophils constitutively express a second low-affinity IgG
receptor, the FcγRIIA. Albeit less abundant than FcγRIIIB,
each neutrophil expresses between 30,000 and 60,000 copies
of FcγRIIA (19). Interestingly, this receptor was described to
have a lower affinity for IgG on resting than on primed or
activated neutrophils (39), a feature that has been attributed to
its interactions with integrins (40). Upon efficient cross-linking
of FcγRIIA in vitro, neutrophils become activated, degranulate,
and produce inflammatory mediators and ROS and trigger
neutrophil extracellular trap (NET) formation (27, 41–44). More
recent data, however, suggest that resting neutrophils rather
poorly respond to FcγRIIA-induced activation. One possible
explanation for these divergent observations may be found in
the purification techniques used to isolate neutrophils. Indeed,
density gradient centrifugation or dextran sedimentation used to
be the standard techniques. Nowadays, neutrophils are mostly
isolated by negative selection procedures that maintain the cells
in isotonic buffer, but expose them to magnetic fields. Indeed,
while comparative data between the procedures are sparse (45,
46), possible differences in neutrophil priming and purity need
to be taken into account when interpreting the data.
In contrast to the abundant FcγRIIIB and FcγRIIA,
neutrophils express less than 2,000 copies of the high-affinity
FcγRI (19). Ligation of FcγRI on resting neutrophil with a specific
antibody does not induce a significant degree of cell activation
(47) and neutrophils show poor binding to monomeric IgG1 and
phagocytosis of IgG-opsonized particles (48, 49). Neutrophils
can also express FcγRIIB; however, its detection is variable
among individuals ranging from low to undetectable (27, 50).
Although it is well-established that co-engagement of FcγRIIB
potently inhibits FcγR-driven cell activation (15–17), it is
questionable if the low expression of FcγRIIB on neutrophils
could oppose signals generated by the other FcγRs in this
context. Finally, a very recent report suggests that neutrophils
may also express modest amounts of FcγRIIIA (51), a receptor
that was previously thought to be exclusively expressed by NK
cells and monocytes (52). In this study, the authors report that
FcγRIIIA engagement on neutrophils from FcγRIIIB-deficient
and normal individuals efficiently triggers cell activation and
mediates phagocytosis of IgG-opsonized beads that could not be
blocked by anti-FcγRIIA F(ab′)2 fragments (51). Many different
groups have studied FcγR expression on neutrophils before, but
were incapable to affirm FcγRIIIA expression. This might be due
to the fact that most antibodies used to study FcγRIII recognize
both FcγRIIIA and FcγRIIIB, and that FcγRIIIB deficiency is
rare. In a study from 1994, one can however appreciate some
residual FcγRIII [3G8] staining on neutrophils from paroxysmal
nocturnal hemoglobinuria patients [a disorder characterized by
the deficiency of glycosyl phosphatidylinositol (GPI)-anchored
proteins in blood cell membranes] and an FcγRIIIB-deficient
patient, as well as on neutrophils treated with GPI-phospholipase
C as compared to an isotype control (53). This residual binding,
if specific, could support the hypothesis of a low expression
of FcγRIIIA on neutrophils. The central piece of evidence for
FcγRIIIA expression on neutrophils in the recent report is a
single FcγRIIIB-deficient donor, whose genotype was confirmed
by RT-PCR and not by sequencing of the FcγR locus. This allows
speculation about a cryptic FcγRIIIB expression in this donor.
Furthermore, if a low expression of FcγRIIIA can be confirmed
in other FcγRIIIB-deficient donors, it will be necessary to clarify
to what extent it can contribute to neutrophil effector functions
in vivo. One point is certain, this study refuels the discussion
about the capacity of FcγRIIIB to trigger cell activation and
suggests that neutrophil activation observed following receptor
cross-linking with anti-FcγRIII F(ab′)2 fragments or ICs can be
rather attributed to FcγRIIIA than to the GPI-anchored receptor.
NEUTROPHIL FCγR IN AN
INFLAMMATORY CONTEXT
Neutrophil FcγR expression can change dramatically in the
context of an inflammation or infection. Notably, FcγRI is
strongly upregulated in the presence of inflammatory cytokines
such as interferon-γ (IFN-γ) or granulocyte colony-stimulating
factor reaching up to 20,000 copies per cell (19, 48, 54, 55). This
confers neutrophils the capacity to efficiently bind monomeric
IgG (48), phagocytose IgG-opsonized bacteria (49), exert anti-
fungal functions (56), and induce ROS production in response
to FcγRI cross-linking (47). FcγRI upregulation also enables
neutrophils to efficiently trigger antibody-dependent cytotoxicity
(ADCC) (55). As a consequence, neutrophil FcγRI expression
has been shown to reflect infection state and disease activity in
numerous inflammatory conditions (57–61), and a low CD64
expression is a marker for sustained remission in Crohn’s disease
patients receiving infliximab (62). Consecutively, neutrophil
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CD64 has been discussed as an interesting biomarker, especially
in the case of sepsis (57). Sepsis diagnosis includes a blood
culture that allows specific identification of the disease-causing
bacteria and their antibiotic resistances, but takes up to 2 days
to generate results. Precious time, during which patients with
sepsis suspicion commonly receive broad-spectrum antibiotics
to avoid deterioration of their condition. This common practice
has it flaws, because antibiotics are not adapted in case of
non-bacterial infections, and because some bacteria require
specific antibiotics and are not targeted by broad-spectrum ones.
Certainly, inappropriate use of antibiotics contributes to the
increase of antibiotic resistance among different bacteria that has
been classified as “one of the biggest threats to global health,
food security, and development today” by the WHO. Neutrophil
CD64 expression was proposed as a way to detect infection so
that timely decisions and treatment refinement can be made.
Neutrophil CD64 can be evaluated within 1–2 h, making it a
rapid diagnostic and prognostic marker. Indeed, a study reported
not only elevated CD64 expression in septic patients compared
to healthy controls, but also a decrease in CD64 expression
following treatment with an appropriate antibiotic compared
to inefficient treatment (63). However, not all studies find in
neutrophil CD64 a reliable marker for sepsis detection, and
different studies report divergent sensitivity and specificity for
sepsis detection by neutrophil CD64 (64–67). Two meta-analyses
report a large heterogeneity in study design and results (68, 69).
This may be due to the fact that this test can be run in any
laboratory with a flow cytometer and that the results can be
expressed either as percentage of neutrophils expressing CD64 or
as mean fluorescent intensity of the whole neutrophil population.
In the absence of a standardized assay, each laboratory needs
to establish its own cutoff. Furthermore, confounding factors
(previous use of antibiotics, delayed culture collection, etc.)
may result in a negative result from the microbiological test
that, as a consequence, poses problems with the classification
of the patients. Given the low costs of the assay, neutrophil
CD64 remains an interesting candidate to monitor in case of
sepsis suspicion. Larger prospective studies are however required
to conclude on its sensitivity and suitability as a biomarker,
especially in light of new approaches for sepsis diagnosis and the
evolution of our understanding of sepsis as a condition involving
not only the bacterial infection and its resulting immune
response, but also changes in coagulation, immunosuppression,
and organ dysfunction (70).
IFN-γ treatment has little effect on neutrophil FcγRIIA
expression but can induce FcγRIIB expression (albeit on a low
level) and, depending on the experimental conditions, may
induce FcγRIIIB down-modulation (19, 71). FcγRIIA expression
on neutrophils may however be induced by TNF-α (72).
As a consequence, primed neutrophils and neutrophils from
individuals with inflammatory conditions show enhanced FcγR-
dependent responses (73–75).
Finally, IgG ICs can also be at the onset of inflammation,
allergic reactions, and autoimmunity (76, 77). This is notably
the case, when the amounts of circulating ICs suddenly rise
and exceed the body’s capacity to silently remove them, when
ICs form that are insoluble and “precipitate” onto endothelial
cells, or when autoantibodies bind to large surfaces, i.e., cartilage,
thereby opsonizing phagocytosis-resistant structures. All these
conditions can be mimicked in vitro and helped to understand
that soluble ICs require primed neutrophils to efficiently trigger
external ROS production and degranulation, while insoluble
ICs can activate unprimed neutrophils, leading to intracellular
ROS production, degranulation, and sustained liberation of
inflammatory mediators such as IL-8 and leukotriene B4
(LTB4) that sustain neutrophil-driven inflammation (73, 78).
An elegant study, using transgenic mice expressing either
FcγRIIA or FcγRIIIB or both in the absence of endogenous
activating FcγR, demonstrated that FcγRIIIB has a primordial
role in the homeostatic removal of soluble ICs within the
vasculature, whereas FcγRIIA engagement by soluble ICs in
tissues generates NETs, a pro-inflammatory process linked to
autoimmunity (27, 44). Engagement of either FcγR by deposited
ICs leads to neutrophil accumulation (44). These data illustrate
the specialized role of FcγRs in triggering neutrophil effector
functions, despite their overlapping binding properties to IgG.
GENETIC VARIATIONS AFFECTING
NEUTROPHIL FCγR EXPRESSION AND
FUNCTIONS
A number of polymorphisms have been identified in the FCGR
loci that affect their biological functions and may consequently
impact the individual’s susceptibility for diseases and their
capacity to respond to therapies based onmonoclonal antibodies.
This is notably the case for polymorphisms that alter the affinity
of FcγRs for IgG, thus directly affecting their capacity to clear
immune complexes.
Until today, no polymorphism of FcγRI has been identified
that modifies the affinity of the receptor for IgG or its
associated functions. In contrast, the low-affinity IgG receptor
locus on chromosome 1q23.3 coding for all FCGR2/3 genes is
home to multiple genetic variants, including single-nucleotide
polymorphisms (SNPs) and copy number variations (CNVs).
These genetic variants display heterogeneity among ethnic
groups (79). The best-characterized polymorphism of FCGR2A
results in substitution of an arginine residue by a histidine at
position 131 (rs1801274) that results in a receptor variant with
an improved binding to IgG2 (and to a lesser extent to IgG1 and
IgG3) (80). The FCGR2A-R131 variant is therefore expected to
show lower clearance of IgG immune complexes and is indeed
associated with susceptibility to auto-immune disorders (81–
85) and recurrent bacterial infections with encapsulated bacteria
(86). The FCGR2A-H131 variant, on the other hand, predisposes
individuals to Kawasaki disease and Myasthenia gravis (87, 88).
More recently, a splice variant of FCGR2A, FcγRIIa(exon6*), has
been described that retains a cryptic exon in the cytoplasmic
tail of the receptor (89, 90). This results in a gain-of-function
allele that increases neutrophil sensitivity to IgG stimulation
and hence predisposes to anaphylactic reactions following IVIg
infusions in patients with hypogammaglobulinemia (71). As
described above, FcγRIIB is poorly expressed on neutrophils
(50). A specific haplotype in the promoter region, termed 2B.4,
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was shown to augment FcγRIIB expression on myeloid cells,
including neutrophils (91). This promoter variant enables a more
efficient binding of the transcription factors GATA4 and Yin-
Yang1, resulting in a higher promoter activity and hence higher
FcγRIIB expression (92). Surprisingly, this gain-of-function
promoter haplotype was found to be associated with systemic
lupus erythematous (SLE) (91). A possible explanation might
reside in an FcγRIIB-dependent inhibition of IC-phagocytosis,
but experimental data to support this hypothesis are still missing.
Additionally, a polymorphism of FCGR2B (rs1050501) results
in the replacement of a threonine by an isoleucine in the
transmembrane domain (I232T). The presence of threonine in
that position entails a failure of FcγRIIB to enter lipid rafts and,
as a consequence, reduces its ability to inhibit activatory receptors
(93). For FCGR3B, three different allotypes have been described,
resulting from five non-synonymous polymorphisms that all
affect the neutrophil antigen (NA) located in the membrane-
distal Ig-like domain. These variants are termed NA1 (R36 N65
A78 D82 V106), NA2 (S36 S65 A78 N82 I106), and SH (S36 S65
D78 N82 I106) (94). They do not result in detectable differences
in affinity for hIgG subclasses (10). The NA1 allotype was
nevertheless reported to increase phagocytosis of IgG-opsonized
particles (95) and is associated with a reduced responsiveness
to IVIG therapy in Kawasaki disease (96). The SH allotype is
the rarest allele and less well-characterized. Recently, it has been
reported to be associated to increased FCGR3B copy numbers
(79) that could account for the higher FcγRIIIB expression levels
described earlier (97).
A rather large number of studies have associated a single
FcγR polymorphism with the induction or severity of antibody-
related diseases, or the efficacy of antibody-based therapies.
It is however important to bear in mind that all low-affinity
IgG receptors are encoded in a single locus on chromosome 1
(1q23). Indeed, a high degree of linkage disequilibrium has been
reported for the FCGR2/3 locus (79, 98, 99) that are strongly
linked to ethnic background (79). Association studies should
therefore take into account the entire locus and not investigate
an isolated gene (100). Adding to the complexity of the 1q23
locus, gene copy number variations (CNVs) have been described
for FCGR3A, FCGR3B, and FCGR2C that directly impact the
expression level of the receptors (97). These CNV can include
deletions of parts of the locus, giving rise to FCGR2A/2C chimeric
genes, reducing the expression and function (ROS induction)
of the resulting receptor (101). CNVs of FCGR3B have been
associated to a number of autoimmune disorders, including SLE,
rheumatoid arthritis, and systemic auto-immunity (102–106).
Indeed, fewer than two copies of FCGR3B have been associated
to SLE susceptibility (107, 108), which has been confirmed in
meta-analysis (109, 110).
Lastly, 0.03–0.1% of the population show a deficiency of
FCGR3B (and the FCGR2C gene) (101, 107). While most
studies did not find an association of the FCGR3Bnull genotype
with a disease phenotype, one report suggested an association
with SLE (102, 111, 112). This apparent contradiction with
the finding that low copy numbers increase SLE susceptibility
could be due to the low frequency of this genotype in the
population, resulting in an insufficient power for calculation.
On the other hand, FcγRIIIB-deficient individuals were included
at the estimated frequency in a selective cohort of healthy
donors with a long list of exclusion criteria, suggesting that
FcγRIIIB deficiency remains undetected in most carriers (113).
This suggests that FCGR3B deficiency does not directly cause
disease, but possibly aggravates disease pathogenesis when ICs
are accumulating.
REGULATION OF NEUTROPHIL FCγRS
The best-described pathway of inhibiting activating FcγRs
is, without doubt, through co-engagement of the inhibitory
FcγRIIB by the same immune complexes (114, 115). However,
as mentioned earlier, human neutrophils express little to
no FcγRIIB (50), and it appears therefore mandatory that
neutrophils rely on other mechanisms to regulate their activation
by FcγRs.
Recently, several groups have reported that the glycosylation
state of the IgG antibodies significantly modifies their affinity
for FcγRs (116–118). Indeed, all human IgG contain a single N-
linked glycan positioned at asparagine 297 in the antibody Fc
portion, which is critical for their interaction with FcγRs. Several
studies have illustrated how the composition of the Fc glycan
influences IgG effector functions (119, 120) (Figure 1A). As an
example, IgG Fc glycans lacking fucose display a greatly enhanced
affinity to the FcγRs, FcγRIIIA, and FcγRIIIB, compared to
fucosylated IgG. Besides their well-established improvement
of NK cell-dependent ADCC in vivo (121–123), afucosylated
IgG used to opsonize target cells also activate neutrophils
more efficiently than wild-type IgG, inducing pro-inflammatory
cytokines and phagocytosis of target cells, but no ROS production
or antibody-dependent cellular cytotoxicity activity (124).
Addition of an afucosylated anti-CD20 mAb (obinutuzumab) to
blood samples from RA and SLE patients resulted in a superior
B cell deletion than wt anti-CD20 mAb, concomitantly with
neutrophil and NK cell activation (125), suggesting that both
cells cooperate to eliminate target cells in vitro. Opposing these
results, another study reported FcγRIIIB-dependent inhibition
of neutrophil ADCC or trogocytosis of solid cancer cells coated
with either anti-HER2 mAb (trastuzumab) or anti-EGFR mAb
(cetuximab). Notably, copy numbers of FcγRIIIB could be linked
to the inhibitory effect and blocking FcγRIIIB with F(ab′)2 3G8
improved target cell killing (126). Further studies are required
to determine whether these discrepancies depend on the target
cell (solid tumor vs. hematological) and how neutrophil FcγRIIIB
(and FcγRIIIA) (51) contribute to cancer elimination in vivo.
Terminal sialylation of the Fc glycan, instead, decreases the
affinity for activating FcγRs (while maintaining the affinity for
inhibitory FcγRIIB), and sialylated IgG has reduced capacity
to initiate ADCC in vivo (118, 127). This might explain why
antibodies against autoantigens can often be detected months
to years before the first sign of an autoimmune inflammation
(128–130). De-sialysation of these antibodies might therefore
be a hallmark of autoimmune disease progression (131, 132).
In this context, it is noteworthy that a recent report evidenced
the potential of in vivo glycan engineering of antibodies to
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FIGURE 1 | Schematic representation of proposed mechanisms that regulate FcγR activity on neutrophils. (A) IgG glycosylation determines its affinity for FcγRs, (B)
Mac-1 regulates FcγRIIA affinity for IgG, (C) CD300a-mediated FcγRIIA inhibition, (D) C-reactive protein (CRP)-driven FcγRIIA down-regulation, (E) FcγRIIIB shedding
by ADAM17, and (F) Interplay between Toll-like receptors (TLR)7/8 and FcγRIIA.
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modulate of IgG effector functions. Indeed, application of
soluble glycosyl-transferases could reduce autoantibody-induced
inflammation in models of arthritis and nephrotoxic nephritis
(133). However, it remains to be determined whether these
very promising findings are exclusively due to IgG glycan
modulation or the result of a more complex alteration of multiple
glycan structures.
Sialic acid residues have recently been reported to contribute
to anothermechanism of FcγR regulation (Figure 1B). Prompted
by the finding that CD18-deficient neutrophils show an enhanced
recruitment to IgG-coated endothelium (134) and that an SNP
in the CD18 integrin Mac-1 (rs1143679) is a risk factor for
SLE (135), Saggu et al. investigated the interaction between
FcγRIIA andMac-1 on the cell surface. The authors convincingly
show that the extracellular portion of Mac-1 in its inactive
bend configuration interacts with sialylated FcγRIIA on resting
neutrophils and thereby lowers the affinity of the receptor for
IgG (40). Interestingly, once the interaction between FcγRIIA
and IgG is sufficiently strong to overcome this increased
activation threshold, Mac-1 assists FcγRIIA to induce cell
spreading (136). This study provides a mechanistic explanation
for the observation made earlier that FcγRIIA appears to have
a lower affinity for IgG on resting neutrophils than on pre-
activated ones.
Othermolecules have been suggested to interact andmodulate
FcγRIIA activity. These include the ITIM-containing CD300a
that can be rapidly mobilized from an intracellular pool to the
surface of peripheral blood neutrophils following stimulation.
Co-engagement of CD300a and FcγRIIA reduced FcγRIIA-
dependent activation in an in vitro system (137) (Figure 1C).
Furthermore, two plasma proteins produced in the liver during
the acute phase of inflammations were described to interact
with FcγRIIA (and FcγRIIIB), the C-reactive protein (CRP)
and the serum amyloid P (SAP) component (138, 139). CRP
preferentially interacts with the FcγRIIA-R131-allele and can act
like an opsonin, triggering the uptake of CRP-coated particles
(140) (Figure 1D). Interestingly, IgG ICs can reduce CRP
binding to FcγRIIA, whereas the reverse is not true (141). SAP
was similarly described to act as an opsonin that could enhance
phagocytosis via FcγRs (139). Additionally, it was described
to reduce neutrophil adhesion by binding to FcγRIIA (142).
Whether SAP binding can regulate IgG-dependent FcγRIIA
activation remains however to be determined.
Another possibility to modulate FcγR-induced cell activation
is to regulate receptor availability on the cell surface. This
can be achieved by receptor internalization (8, 90, 93),
translocation from intracellular storage compartments to the
cell surface (22), or shedding of the extracellular portion of
the FcγR. This latter phenomenon is best documented for
FcγRIIIB, which is rapidly and efficiently cleaved from the
cell surface following neutrophil stimulation (143), and during
neutrophil apoptosis (34, 35). The main protease responsible
for this ectodomain shedding appears to be ADAM17 (A
Desintegrin and Metalloprotease-17) (144) that is rapidly
activated following multiple cell stimulating pathways, such as
FcγR/CR-dependent phagocytosis or stimulation with fMLP or
PMA (145) (Figure 1E). ADAM17 activation appears to require
activation of caspase 8 and mitochondrial ROS production
(146). Supporting an important role for the regulation of cell
activation by ADAM17, ADAM17 deficiency in humans has been
associated with severe inflammatory disorders of the skin and the
gut, resulting in recurrent sepsis and poor survival (147, 148).
Similar to the ectodomain shedding of FcγRIIIB, reduction of
surface FcγRIIA on Langerhans cells and activated neutrophils
has been described (39, 149). These initial observations have
recently gained attention by the demonstration that TLR-induced
activation resulted in the cleavage of extracellular FcγRIIA on
the neutrophil surface, thus removing the N-terminal portion
of the receptor (150) (Figure 1F). This cleavage has functional
consequences for the neutrophils. It reduces their phagocytic
activity, while augmenting their propensity to produce NETs,
thereby supporting the concept that phagocytosis and NETosis
could be neutrophil effector functions that oppose each other,
as had been suggested by the finding that NETosis was reduced
when microbes where small enough to be phagocytized (151).
Similarly, neutrophils from SLE patients and especially their low-
density granulocytes that were reported to spontaneously release
NETs (152) seem to express less “full-length” FcγRIIA than
neutrophils from healthy donors (150). This might explain why
neutrophils from SLE patients fail to efficiently clear circulating
ICs and are NET-prone (153). The cleavage of the N-terminal
portion of FcγRIIA involves a PI3K-dependent production of
ROS and seems to be mediated by the serin-protease furin
(150); the exact mechanism of its action, however, as well
as the fate and role of the N-terminal fragment of FcγRIIA
following cleavage remains to be discovered. Similarly, questions
on the stability, function, and possibly altered affinity of the
shortened membrane-bound FcγRIIA justify further research in
this area.
Finally, it has been suggested that FcγRIIIB could represent
an efficient modulator of FcγRIIA activity in neutrophils.
Indeed, the weakly signaling FcγRIIIB predominantes FcγRIIA
expression on resting neutrophils. Furthermore, CD16B extends
out further from the cell surface membrane (154, 155), implying
that FcγRIIIB is likely to capture circulating immune complexes,
thus competing with and preventing FcγRIIA–IgG interactions.
The picture is very different with regard to activated neutrophils
that, through FcγRIIIB ectodomain shedding, grant access to
cell-activating FcγRIIA (154).
CROSS-TALK OF NEUTROPHILS AND B
CELLS
Collectively, these studies underline the critical involvement of
IgGs in the modulation of neutrophil activity. Indeed, IgGs
through FcγRs render neutrophils capable to act to threats
to the host in an antigen-specific manner, but are also the
trigger for tissue damage if autoantigens are being targeted.
Interestingly, there is accumulating evidence that neutrophils
are not mere effector cells of the immune system, but actively
shape and modulate immune responses through interactions
with other cells and the release of mediators. In the context of
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IgG-dependent immunity, their recently described interactions
with B cells are of particular interest.
Data from patients receiving G-CSF suggested that
neutrophils can communicate with B cells through production
of BAFF (B cell-activating factor) (156), a molecule known to
sustain B cell survival and responsiveness (157, 158). Similarly,
APRIL (A Proliferation Inducing Ligand) was suggested to
be an important survival proliferation factor for human B
cells, which additionally drives class-switching reactions (159–
161). Neutrophils constitutively secrete APRIL (162), but
circulating neutrophils fail to directly activate B cells. Upon
infection, neutrophil-derived APRIL is retained by heparan
sulfate proteoglycans in mucosal tissues, thereby creating a
niche for local plasma cell survival and sustained antibody
production (163). Similarly, it has been reported that diffuse
large B cell lymphoma secretes chemokines to recruit APRIL-
producing blood neutrophils to the tumor (162) and that
high APRIL concentrations in tumors are correlated with
decreased patient survival rates (164). In SLE, neutrophils
interact with B cells in many different ways. SLE neutrophils
were reported to show increased expression of BAFF, APRIL,
and IFN-α that fuels B cell development and autoantibody
production in the bone marrow. In the circulation, SLE
neutrophils secrete increased amounts of IL-6 upon IFN-α
stimulation that supports survival and maturation of B cells and
plasma blasts (165). Concomitantly, they are also NET-prone
and release LL37–DNA complexes that trigger polyclonal B
cell activation via TLR9, giving rise to more NET-specific
autoantibodies (166).
Neutrophils can also be found in multiple locations of the
spleen, including the perifollicular zone, around the marginal
zone (MZ) and the red pulp (167–170). Their exact role in
each of these compartments is not fully understood. In the
spleen, a specialized subset of neutrophils has been described
that has the capacity to provide B cell support. These “B
cell helper neutrophils” (NBH) are located around the MZ of
healthy human donors and express high levels of the B cell-
stimulating cytokines BAFF, APRIL, and IL-21 in response to
microbial stimuli and thereby provide help to MZ B cells to
trigger antibody production against T cell-independent antigens
(169). In patients with severe congenital neutropenia (SCN),
CD27+IgDlow circulating MZ B cells and levels of IgM, IgG,
and IgA antibodies against T cell-independent antigens were
less abundant than in healthy subjects (169). Contradicting
this report, no NBH could be identified in spleen samples
from organ transplant donors (171); also, similar numbers of
CD27+IgD+memory B cells were reported in patients suffering
from chronic idiopathic neutropenia and healthy subjects (172).
In addition to BAFF and APRIL, Pentraxin3 (PTX3) has been
proposed to be a neutrophil-derived factor that supports B
cell functions (173). PTX3 is stored in secondary granules of
neutrophils and released upon stimulation with Toll-like receptor
agonists (174). PTX3 binds to MZ B cells and enhances the
secretion of class-switched IgG in the presence of BAFF (173).
The capacity of neutrophils to secrete B cell-stimulating factors
enables them to directly interact with the adaptive immune
system and shape antibody responses, which, in turn, can
trigger potent neutrophil effector functions. This underlines
the complexity of our immune system and the multiple layers
of regulation that are at play to efficiently protect us from
external threats.
CONCLUDING REMARKS
Collectively, the discussed literature exemplifies how our
understanding of neutrophils has evolved from their early
descriptions as simple first-line defense cells, equipped with
powerful weapons to defend the host but unable to differentiate
between different threats, to portrayals of cells capable of
tailoring their responses according to their environment.We now
appreciate that neutrophils interact with various other cell types,
integrate complex stimuli, and cooperate with other players
of the immune system to fine-tune their responses. The role
and regulation of FcγR on neutrophils is not an exception to
this rule. Early reports frequently suggested that IgG ICs had
very strong neutrophil-activating capacities, but more recently,
a much more detailed picture has been drawn, taking into
account the size, solubility, composition, and location of ICs.
Furthermore, IgG enables neutrophils to function as antigen-
specific cells; at the same time, accumulating evidence suggest
that neutrophils in turn tune the activity of (at least some)
B cells to regulate antibody production. Much remains to be
discovered and hopefully new techniques will allow us to unravel
previously unappreciated functions of neutrophils and revise
others. We are looking forward to hearing more about these
exciting cells.
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